Facing Down Emerging Viruses

A better knowledge of the pathogenesis of emerging zoonotic diseases is crucial if we want to prepare for “the next Ebola.”

Written byMichal Barski
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

© ISTOCK.COM/ANYAIVANOVAThe disastrous and still ongoing Ebola epidemic in West Africa has highlighted the threat of newly emerged viral infections. As we observe the herculean attempts to contain the infection and the rush to test and approve underdeveloped drugs and vaccines, it is easy to overlook the true lesson to be learned from this situation—namely, how little we know about why and how certain viruses spill over from their natural hosts and how they interact with the human immune system.

Nearly 60 percent of all human pathogens are of zoonotic origin. This includes pathogens that have only very recently jumped to humans—such as Ebola, its emergence first reported several decades ago and again last year—as well as pathogens that have been with our species for hundreds or thousands of years. Smallpox, for example, most likely emerged in Central Africa as early as 2000 BC. Epidemiology tells us that the spread of a pathogen relies on perpetual contact with new groups of susceptible individuals. With the socioeconomic and environmental changes currently taking place, we are creating ideal conditions for the emergence and spread of zoonotic viruses. Moreover, the staggering increase in long-distance mobility (mainly via air travel) allows organisms—from people to pathogens—to jump around the world ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies